宝济药业港股募10亿港元首日涨139% 2年半亏7.1亿元

Core Viewpoint - Baoyi Pharmaceutical Co., Ltd. (宝济药业) has successfully listed on the Hong Kong Stock Exchange, with its stock closing at HKD 63.00, reflecting a significant increase of 138.82% from its initial offering price of HKD 26.38 [1][5]. Group 1: IPO Details - The total number of shares offered globally was 37,911,700 H-shares, with 3,791,200 shares allocated for the Hong Kong offering and 34,120,500 shares for international placement [1]. - The total proceeds from the offering amounted to HKD 1,000.1 million, with net proceeds after estimated listing expenses of HKD 921.5 million [5][6]. Group 2: Use of Proceeds - The net proceeds from the global offering will be utilized for the research and commercialization of core products (including KJ017, KJ103, and SJ02), advancing existing pipeline products, optimizing proprietary synthetic biology technology, and enhancing production capacity [5][6]. Group 3: Financial Performance - For the fiscal years ending December 31, 2023, and 2024, Baoyi Pharmaceutical reported revenues of RMB 6.9 million and RMB 6.2 million, respectively, with net losses of RMB 160.4 million and RMB 364.4 million [6][7]. - The adjusted losses for the same periods were RMB 160.4 million and RMB 205.7 million, indicating ongoing financial challenges despite the recent capital influx [6][8]. Group 4: Key Investors - Key cornerstone investors include Anke Biotechnology (安科生物), Derivatives China Alpha Fund SPC, and Guotai Junan Securities Investment (国泰君安证券投资) [3][4]. - These investors collectively hold approximately 20.06% of the shares post-offering, with Anke Biotechnology holding 11.20% [4].